Posted on December 22, 2011
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to evaluate Cardiovascular Outcomes Following Treatment with Aloglipton in Addition to Standard of Care in Subject with Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in subjects with type 2 diabetes mellitus and acute coronary syndrome
Aloglipton effects on Cardiovascular Outcomes